Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch ‐associated cancers—A population‐based analysis

Women developing endometrial cancer after tamoxifen treatment for breast cancer are more likely to develop tumours with poorer prognostic features and exhibit poorer survival after adjustment for these prognostic features. Results indicate the importance of longer ‐term monitoring of women treated with tamoxifen for cancer symptoms. Report of prior cancer is a significant indicator of MMR pathogenic variant status, but molecular analysis of endometrial tumors at diagnosis is warranted to detect all patients with Lynch Syndrome. AbstractWe hypothesized that endometrial carcinoma (EC) patients with a prior cancer diagnosis, after accounting for EC arising after tamoxifen ‐treated prior breast carcinoma, are more likely to have an underlying genetic basis. We used information from a population‐based study to compare measured risk factors, tumor characteristics, survival, and known mismatch repair (MMR) pathogenic variant status for EC subgroups according to prior diagnosis of cancer (none, breast cancer tamoxifen‐treated or not, Lynch Syndrome (LS)‐associated cancer). Family history of any cancer was increased for EC cases with prior breast cancer, both tamoxifen treated (P = 0.005) and untreated (P = 0.01). EC cases with prior LS‐associated cancer more often reported family history of LS‐associated cancer (P = 0.04) and breast cancer (P = 0.05). EC patients with a germline pathogenic MMR gene variant were more likely to report a prior cancer than cases wit...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research